Je was op zoek naar: rheumatic (Engels - Maltees)

dmard - disease modifying anti-rheumatic drug
dmard - mediċina kontra r-rewmatiżmu li timmodifika l-marda

these are used mainly in rheumatic and autoimmune diseases.
dawn jintużaw primarjament f’mard rewmatiku u awtoimmuni.

methotrexate (used to treat cancer and rheumatic disorders)
methotrexate (użat biex jikkura l-kanċer u disturbi tar-rewmatiżmu)

anti-rheumatic therapies have been associated with hepatitis b reactivation.
terapiji ta ’ kontra r- rewmatiżmu ġew assoċjati ma ’ ri- attivazzjoni ta ’ l- epatite b.

no other disease-modifying anti-rheumatic drugs were allowed.
ma kienx permess it-teħid ta’ mediċini anti-rewmatiċi oħra li taffetwa l-proċess tal-mard.

worsening of rheumatic conditions; pains or difficulties in passing urine.
aggravament ta’ kundizzjonijiet rewmatiċi; uġigħ jew diffikulta biex tgħaddi l-awrina.

arava belongs to a group of medicines called anti-rheumatic medicines.
arava jappartjeni għall-grupp ta’ mediċini msejħa antirewmatiċi.

ulfasalazine: a medicine to treat severe bowel and rheumatic joint inflammation.
ulfasalazine: mediċina għall-kura ta’ infjammazzjoni tal-imsaren severa u għal ġogi rewmatiċi.

leflunomide is a disease-modifying anti-rheumatic agent with antiproliferative properties.
leflunomide huwa sustanza b’karatteristiċi anti-proliferattivi li taġixxi bħala prodott anti- rewmatoloġiku.

methotrexate for the therapy of rheumatic diseases or diseases of the skin must only be used once weekly.
methotrexate għat-terapija ta’ mard rewmatiku jew mardiet tal-ġilda għandu jintuża biss darba fil- ġimgħa.

response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.
• kura ta ’ artrite rewmatika attiva minn moderata sa severa f’ pazjenti adulti, meta r- rispons tagħhom għal mediċini anti- rewmatiċi li jaffetwaw il- proċess tal- mard, inkluż methotrexate, ma kienx adegwat. li l

pharmacotherapeutic group: anti-inflammatory and anti-rheumatic products, non-steroids.
grupp farmako-terapewtiku:prodotti anti-infjammatorji u antirewmatiċi, mhux sterojdi.

trudexa can be taken together with methotrexate or certain disease-modifying anti-rheumatic agents rod
trudexa jista ’ jittieħed flimkien ma ’ methotrexate jew ċerti tipi ta ’ aġenti anti- rewmatiċi li jaffetwaw il- proċess tal- mard (sulfasalazine, hydroxychloroquine, leflunomide u preparazzjonijiet tad- deheb li od

years old and had failed therapy with at least one disease-modifying, anti-rheumatic drugs.
studju ii evalwa 544 pazjent li jbatu minn artrite rewmatika attiva minn moderata sa severa li kellhom ≥ 18 – il sena u li ma kinux irrispondew għal kura b’ mill- inqas mediċina waħda anti- rewmatika li taffetwa l- proċess tal- mard.

regarding combination with disease modifying anti-rheumatic drugs other than methotrexate see sections 4.4 and 5.1.
rigward it-teħid flimkien ta’ humira ma’ mediċini anti-rewmatiċi li jaffetwaw il-proċess tal-mard, minbarra methotrexate, ara sezzjoni 4.4 u 5.1.

the concomitant use of mabthera and anti-rheumatic therapies other than those specified under the rheumatoid arthritis indication and posology is not recommended.
l-użu konkomitanti ta’ mabthera u terapiji anti-rewmatiċi għajr dawk speċifikati taħt l-indikazzjoni u l-pożoloġija għall-artrite rewmatika mhux rakkomandat.

pharmacotherapeutic group: anti-inflammatory and anti-rheumatic products, non-steroids (oxicams).
grupp farmako-terapewtiku: prodotti antiinfjammatorji u antirewmatiċi, mhux sterojdiċi (oxicams).

compared to placebo, patients with rheumatic diseases treated with enbrel had a significantly higher incidence of injection site reactions (36% vs.
imqabbla mal-plaċebo, pazjenti b’mard rewmatiku kkurati b’enbrel kellhom inċidenza b’mod sinifikanti aktar għolja ta’ reazzjonijiet fis-siti ta’ l-injezzjoni (36% vs.

anti-rheumatic drug-naïve or to remain on their pre-existing rheumatologic therapy provided that therapy was stable for a minimum of 28 days.
il- pazjenti kienujew ma jafux li qegħdin jieħdu mediċina anti- rewmatika li taffetwa l- proċess tal- mard, jew tħallew ikomplu jieħdu t- terapija anti- rewmatoloġika li kienu diġà qegħdin jieħdu, u dan sakemm il- kura kienet stabbli għall- perjodu minimu ta ’ 28 ġurnata.

 the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.
kura ta ’ artrite rewmatika attiva minn moderata sa severa f’ pazjenti adulti, meta r- rispons • tagħhom għal mediċini anti- rewmatiċi li jaffetwaw il- proċess tal- mard, inkluż methotrexate, ma kienx adegwat.